VistaGen Therapeutics, Inc. cash flow to debt ratio of -6.36K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

VistaGen Therapeutics, Inc.'s free cash flow has decreased 57.10% from $-42.29M last year to $-66.44M, signaling decreasing performance

VistaGen Therapeutics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

VistaGen Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.03 today, signaling weakened financials

VistaGen Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

VistaGen Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

VistaGen Therapeutics, Inc.'s profit margin has increased (-48.14%) in the last year from -10.58K% to -5.49K%, signaling increasing performance

VistaGen Therapeutics, Inc.'s short-term assets of $46.94M exceed its short-term liabilities of $12.79M

VistaGen Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

VistaGen Therapeutics, Inc.'s return on equity of -133.02%, is lower than 15.00%, indicating bad performance

VistaGen Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

VistaGen Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

VistaGen Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

VistaGen Therapeutics, Inc. has negative free cash flow, indicating cash burn

VistaGen Therapeutics, Inc.'s yearly earnings has decreased 35.53% since last year from $-51.42M to $-69.69M, signaling decreasing performance

VistaGen Therapeutics, Inc.'s yearly revenue has increased 161.11% since last year from $486.00K to $1.27M, signaling increasing performance

ROIC -197.24% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

VistaGen Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

VistaGen Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

VistaGen Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

VistaGen Therapeutics, Inc. has insufficient data to evaluate this check.

VistaGen Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

VistaGen Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

VistaGen Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

VistaGen Therapeutics, Inc. is overvalued relative to its fair value price of -19.33 based on Earnings Fair Value model

VistaGen Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

VistaGen Therapeutics, Inc. has a price-to-book ratio of 0.26x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

VistaGen Therapeutics, Inc. has a price-to-sales ratio of 7.37x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue